Leerink Swann rates Vertex outperform

Vertex Pharmaceuticals Inc. was rated market outperform by Leerink Swann & Co. analyst Howard Liang, who described Vertex's hepatitis C drug VX-950 as one of the few innovative agents in the biotechnology industry pipeline capable of addressing a large unmet medical need and changing the standard of care. Shares of the Cambridge, Mass.-based biotechnology company were up $1.00, or 4.07%, at $25.57 on volume of 2,258,094 shares versus the three-month running average of 1,466,180 shares.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.